Recent advances in targeted therapies in acute myeloid leukemia
Acute myeloid leukemia (AML) is the most common acute leukemia in adults. While survival
for younger patients over the last several decades has improved nearly sixfold with the …
for younger patients over the last several decades has improved nearly sixfold with the …
Antibiotic discovery in the artificial intelligence era
T Lluka, JM Stokes - Annals of the New York Academy of …, 2023 - Wiley Online Library
As the global burden of antibiotic resistance continues to grow, creative approaches to
antibiotic discovery are needed to accelerate the development of novel medicines. A rapidly …
antibiotic discovery are needed to accelerate the development of novel medicines. A rapidly …
[HTML][HTML] Ivosidenib and Azacitidine in IDH1-Mutated Acute Myeloid Leukemia
P Montesinos, C Recher, S Vives… - … England Journal of …, 2022 - Mass Medical Soc
Background The combination of ivosidenib—an inhibitor of mutant isocitrate dehydrogenase
1 (IDH1)—and azacitidine showed encouraging clinical activity in a phase 1b trial involving …
1 (IDH1)—and azacitidine showed encouraging clinical activity in a phase 1b trial involving …
Distinguishing AML from MDS: a fixed blast percentage may no longer be optimal
E Estey, RP Hasserjian… - Blood, The Journal of the …, 2022 - ashpublications.org
Patients with acute myeloid leukemia (AML) have conventionally received more intense
therapy than patients with myelodysplastic syndrome (MDS). Although less intense …
therapy than patients with myelodysplastic syndrome (MDS). Although less intense …
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
The 2010 and 2017 editions of the European LeukemiaNet (ELN) recommendations for
diagnosis and management of acute myeloid leukemia (AML) in adults are widely …
diagnosis and management of acute myeloid leukemia (AML) in adults are widely …
Immune dysfunction signatures predict outcomes and define checkpoint blockade–unresponsive microenvironments in acute myeloid leukemia
Background Immune exhaustion and senescence are dominant dysfunctional states of
effector T cells and major hurdles for the success of cancer immunotherapy. In the current …
effector T cells and major hurdles for the success of cancer immunotherapy. In the current …
Intensive chemotherapy with or without gemtuzumab ozogamicin in patients with NPM1-mutated acute myeloid leukaemia (AMLSG 09–09): a randomised, open-label …
H Döhner, D Weber, J Krzykalla, W Fiedler… - The Lancet …, 2023 - thelancet.com
Background Acute myeloid leukaemia with mutated NPM1 is associated with high CD33
expression and intermediate-risk cytogenetics. The aim of this study was to evaluate …
expression and intermediate-risk cytogenetics. The aim of this study was to evaluate …
CircZBTB46 Protects Acute Myeloid Leukemia Cells from Ferroptotic Cell Death by Upregulating SCD
F Long, Z Lin, Q Long, Z Lu, K Zhu, M Zhao, M Yang - Cancers, 2023 - mdpi.com
Simple Summary It is urgent to identify new biomarkers for diagnosis, prognostication, and
therapeutic targets of acute myeloid leukemia (AML) so as to develop more effective …
therapeutic targets of acute myeloid leukemia (AML) so as to develop more effective …
Treatment of older adults with FLT3-mutated AML: Emerging paradigms and the role of frontline FLT3 inhibitors
NJ Short, D Nguyen, F Ravandi - Blood cancer journal, 2023 - nature.com
FLT3 is the most frequently mutated gene in acute myeloid leukemia (AML), with FLT3
internal tandem duplication (ITD) mutations being associated with a more aggressive clinical …
internal tandem duplication (ITD) mutations being associated with a more aggressive clinical …
Small molecule inhibitors targeting the cancers
Compared with traditional therapies, targeted therapy has merits in selectivity, efficacy, and
tolerability. Small molecule inhibitors are one of the primary targeted therapies for cancer …
tolerability. Small molecule inhibitors are one of the primary targeted therapies for cancer …